Please assess the completion status of the following clinical trial:

Trial Title: Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-IV criteria for nicotine dependence with FTND score \> 5.~* Smoke at least 15 cigarettes (3/4 pack) daily (averaged over 1 week, in the past 1 month).~* At the time of initial evaluation, are motivated to quit smoking in the next 30 days.~* Have made at least one unsuccessful attempt to quit smoking in the past year.~* At baseline, have expired breath CO level \> 10.~* Are between ages 18-70 years old.~* Weigh at least 100 lbs (45.5 kg, selegiline dose \< 0.22 mg/kg).~* No previous use of nicotine replacement products in the one month prior to randomization.~* Have the capacity to give informed consent, and are English-speaking.~Exclusion Criteria:~* Have present or past diagnoses of schizophrenia, bipolar disorder, PTSD, BPD or major depressive illness.~* Have abused alcohol or other drugs of abuse (cocaine, opiates, benzodiazepines, etc) in 6 months prior to randomization into the trial (based on clinical evaluation including self-report, and confirmed by positive urine).~* Demonstrate serious medical conditions (i.e. abnormal liver function \[as evidenced by AST, ALT or bilirubin values 2x ULN\], unstable cardiovascular disease, significant blood abnormalities).~* Exhibit or have history of clinical hypertension.~* Exhibit active peptic ulcer disease.~* Are pregnant, are trying to become pregnant, or are currently breastfeeding.~* Are on current medication regimes that include antidepressants, or sympathomimetic agents, or meperidine and other meperidine-opioids which may have interactions with selegiline.~* Known hypersensitivity to selegiline or NRT.~* Are from the same household as another study participant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).